Back to top
more

Aspen Pharmacare (APNHY)

(Delayed Data from OTC)

$11.29 USD

11.29
2

0.00 (0.00%)

Updated Apr 25, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (174 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for APNHY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Aspen Pharmacare falls in the month of June.

All items in Millions except Per Share data.

6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Assets          
Cash & Equivalents 615 407 557 457 633
Receivables 789 830 697 852 882
Notes Receivable 0 0 0 0 0
Inventories 1,106 1,037 874 1,057 1,033
Other Current Assets 0 0 4 0 1
Total Current Assets 2,510 2,274 2,132 2,366 2,549
Net Property & Equipment 1,043 1,047 967 917 851
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 89 82 86 110 82
Intangibles 3,875 3,860 3,880 5,050 5,014
Deposits & Other Assets 34 45 60 95 128
Total Assets 7,574 7,328 7,151 8,576 8,623
Liabilities & Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 574 662 601 624 674
Current Portion Long-Term Debt 446 768 1,604 406 581
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 51 40 0 0 0
Other Current Liabilities 235 70 191 134 158
Total Current Liabilities 1,306 1,539 2,396 1,164 1,413
Mortgages 0 0 0 0 0
Deferred Taxes/Income 113 129 118 174 144
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,206 696 17 2,320 2,800
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 86 295 341 461 444
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,710 2,660 2,873 4,119 4,801
Shareholders Equity 6/30/2023 6/30/2022 6/30/2021 6/30/2020 6/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 94 117 122 122 135
Capital Surplus 0 0 0 0 0
Retained Earnings 3,279 3,576 4,157 2,957 2,908
Other Equity 1,491 975 0 1,378 779
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 4,864 4,668 4,279 4,458 3,822
Total Liabilities & Shareholder's Equity 7,574 7,328 7,151 8,576 8,623
Total Common Equity 4,864 4,668 4,279 4,458 3,822
Shares Outstanding 446.20 446.20 456.40 456.40 456.00
Book Value Per Share 10.90 10.46 9.38 9.77 8.38

Fiscal Year End for Aspen Pharmacare falls in the month of June.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 615 -99,999
Receivables NA NA NA 789 NA
Notes Receivable NA NA NA 0 NA
Inventories NA NA NA 1,106 NA
Other Current Assets NA NA NA 0 NA
Total Current Assets NA NA NA 2,510 NA
Net Property & Equipment NA NA NA 1,043 NA
Investments & Advances NA NA NA 0 NA
Other Non-Current Assets NA NA NA 0 NA
Deferred Charges NA NA NA 89 NA
Intangibles NA NA NA 3,875 NA
Deposits & Other Assets NA NA NA 34 NA
Total Assets NA NA NA 7,574 NA
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA 0 NA
Accounts Payable NA NA NA 574 NA
Current Portion Long-Term Debt NA NA NA 446 NA
Current Portion Capital Leases NA NA NA 0 NA
Accrued Expenses NA NA NA 0 NA
Income Taxes Payable NA NA NA 51 NA
Other Current Liabilities NA NA NA 235 NA
Total Current Liabilities NA NA NA 1,306 NA
Mortgages NA NA NA 0 NA
Deferred Taxes/Income NA NA NA 113 NA
Convertible Debt NA NA NA 0 NA
Long-Term Debt NA NA NA 1,206 NA
Non-Current Capital Leases NA NA NA 0 NA
Other Non-Current Liabilities NA NA 86 NA
Minority Interest (Liabilities) NA NA NA 0 NA
Total Liabilities NA NA NA 2,710 NA
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA 0 NA
Common Stock (Par) NA NA NA 94 NA
Capital Surplus NA NA NA 0 NA
Retained Earnings NA NA NA 3,279 NA
Other Equity NA NA NA 1,491 NA
Treasury Stock NA NA NA 0 NA
Total Shareholder's Equity NA NA NA 4,864 NA
Total Liabilities & Shareholder's Equity NA NA NA 7,574 NA
Total Common Equity 0 0 0 4,864 0
Shares Outstanding 446.20 446.20 446.20 446.20 446.20
Book Value Per Share 0.00 0.00 0.00 10.90 0.00